The authors report a clinical study of the efficacy of a butyrophenone derivative (haloperidol) in a sample of mentally retarded children with associated emotional disturbances. The drug was noted to significantly alter the major target symptoms of such emotional disturbances. It appears that haloperidol is a welcome addition to the slowly growing armamentarium of effective psychopharmacological agents for the emotionally disturbed mentally retarded.Abstract Teaser